The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 156, Issue 3 I, 1997, Pages 895-900

  Donald, Peter R ^b   Sirgel, Frederick A ^b   Botha, Frederick J ^b   Seifart, Heiner I ^b   Parkin, Donald P ^b   Vandenplas, Michel L ^b   Van De Wal, Bernard W ^b   Maritz, Johannes S ^b   Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ACETYLATOR PHENOTYPE; ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM ANALYSIS; TUBERCULOSIS;

EID: 0030805449     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.156.3.9609132     Document Type: Article

References (27)

1. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
2. Sirgel, F. A., F. J. H. Botha, D. P. Parkin, B. W. Van de Wal, P. R. Donald, P. K. Clark, and D. A. Mitchison. 1993. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J. Antimicrob. Chemother. 32:867-875.
3. Chan, S. L., W. W. Yew, W. K. Ma, D. J. Girling, V. R. Aber, D. Felmingham, B. W. Allen, and D. A. Mitchison. 1992. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tubercle 73:33-38.
4. Botha, F. J. H., F. A. Sirgel, B. W. Van de Wal, D. P. Parkin, P. R. Donald, R. Schall, and D. A. Mitchison. 1996. Early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis compared to that of isoniazid. Tubercle 76(Suppl. 2):86.
5. Seifart, H. I., W. I. Gent, D. P. Parkin, P. P. van Jaarsveld, and P. R. Donald. 1995. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J. Chromatogr. [B] 674:269-275.
6. Parkin, D. P., S. Vandenplas, F. J. Botha, M. L. Vandenplas, H. I. Seifart, P. D. van Helden, B. J. van der Walt, P. R. Donald, and P. P. van Jaarsveld. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722.
7. Vatsis, K. P., W. W. Weber, D. A. Bell, J.-M. Dupret, D. A. Price Evans, D. M. Grant, D. W. Hein, H. J. Lin, U. A. Meyer, M. V. Relling, E. Sim, T. S. Suzuki, and Y. Yamazoe. Nomenclature for N-acetyltransferases. 1995. Pharmacogenetics 5:1-17.
8. Dean, A. G., J. A. Dean, D. Coulombier, K. A. Brendel, D. C. Smith, A. H. Burton, R. C. Dicker, K. Sullivan, R. F. Fagan, and T. G. Arner. 1994. Epi Info, version 6: a word processing, database, and statistics program for epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, GA.
9. Mitchison, D. A., and G. A. Ellard. 1978. Antituberculous drugs. In D.S. Reeves, I. Phillips, J. D. Williams, and R. Wise, editors. Laboratory Methods in Antimicrobial Chemotherapy. Churchill Livingstone, Edinburgh. 244-248.
10. Devadatta, S., A. L. Bhatia, R. H. Andrews, W. Fox, D. A. Mitchison, S. Radhakrishna, C. V. Ramakrishnan, J. B. Selkon, and S. Velu. 1961. Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. Bull. W.H.O. 25:807-829.
11. Winder, F. G. 1983. Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria. In C. Ratledge and J. Stanford, editors. The Biology of the Mycobacteria. Vol. 1. Academic Press, London. 395-408.
12. Tuberculosis Chemotherapy Centre, Madras. 1960. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull. W.H.O. 23:535-585.
13. Tuberculosis Chemotherapy Centre, Madras. 1963. The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis. 2: an assessment of the prophylactic effect of pyridoxine in low dosage. Bull. W.H.O. 29:457-481.
14. Mitchison, D.A. 1973. Plasma concentrations of isoniazid in the treatment of tuberculosis. In D. S. Davies and B. N. C. Pritchard, editors. Biological Effects of Drugs in Relation to Their Plasma Concentrations. Macmillan, London. 171-182.
15. East African/British Medical Research Council. 1966. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa - fourth investigation: the effect of increasing the dosage of isoniazid. Tubercle 47:315-339.
16. Miorner, H., and B. Olsson. 1988. Improved isolation of mycobacteria other than Mycobacterium tuberculosis on isoniazid-containing Lowenstein-Jensen medium. Eur. J. Clin. Microbiol. 7:47-49.
17. Hoffner, S. E., and U. Hjelm. 1991. Increased growth of Mycobacterium malmoense in vitro in the presence of isoniazid. Eur. J. Clin. Microbiol. 10:787-788.
18. Long, M. W., D. E. Snider, and L. S. Farer. 1979. U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am. Rev. Respir. Dis. 119:879-894.
19. Selkon, J. B., S. Devadatta, K. G. Kulkarni, D. A. Mitchison, C. N. Nair, and K. Ramachandran. 1964. The emergence of isoniazid-resistant cultures in patients with pulmonary tuberculosis during treatment with isoniazid alone or isoniazid plus PAS. Bull. W.H.O. 31:273-294.
20. Tuberculosis Chemotherapy Centre, Madras. 1970. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. W.H.O. 43:143-206.
21. Mitchison, D. A., and J. M. Dickinson. 1971. Laboratory aspects of intermittent drug therapy. Postgrad. Med. J. 47:737-741.
22. Ellard, G. A., M. J. Humphries, and B. W. Allen. 1993. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 148:650-655.
23. Beggs, W. H., and J. W. Jenne. 1969. Isoniazid uptake and growth inhibition of Mycobacterium tuberculosis in relation to time and concentration of pulsed drug exposures. Tubercle 50:377.
24. Awaness, A. M., and D. A. Mitchison. 1973. Cumulative effects of pulsed exposures of Mycobacterium tuberculosis to isoniazid. Tubercle 54:153-158.
25. Elliott, A. M., S. E. Berning, M. D. Iseman, and C. A. Peloquin. 1995. Failure of drug penetration and acquisition of drug resistance in chronic tuberculosis empyema. Tubercle 76:463-467.
26. Kennedy, N., R. Fox, G. M. Kisyombe, A. O. S. Saruni, L. O. Uiso, A. R. C. Ramsay, F. I. Ngowi, and S. H. Gillespie. 1993. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am. Rev. Respir. Dis. 148:1547-1551.
27. Mitchison, D. A. 1992. The Garrod Lecture. Understanding the chemotherapy of tuberculosis - current problems. J. Antimicrob. Chemother. 29:477-493.